Moderna's combined coronavirus, flu vaccine receives approval in Europe

BRUSSELS

The European Medicines Agency's (EMA) human medicines committee on Friday recommended the approval of a combined coronavirus and seasonal influenza vaccine developed by Moderna for adults aged 50 and over.

The vaccine, known as mCombriax, is the first mRNA‑based combination vaccine to receive a positive opinion from European regulators, according to a statement.

Clinical data showed that recipients of the combined vaccine generated immune responses comparable to those who received separate influenza and Covid‑19 shots, European health authorities said.

The EMA recommendation now goes to the European Commission for final approval, a step that is typically procedural before the vaccine can be marketed across the EU.

If authorized, the vaccine would be available for use in all EU member states and in the broader European Economic Area, health officials noted, offering a new tool in efforts to protect older populations from respiratory illnesses during peak seasons.

BRUSSELS

The vaccine, known as mCombriax, is the first mRNA‑based combination vaccine to receive a positive opinion from European regulators, according to a statement.

Clinical data showed that recipients of the combined vaccine generated immune responses comparable to those who received separate influenza and Covid‑19 shots, European health authorities said.

The EMA recommendation now goes to the European Commission for final approval, a step that is typically procedural before the vaccine can be marketed across the EU.